Vertex Pharmaceuticals Incorporated

292.55+9.05+3.19%Vol 3.02M1Y Perf 47.70%
Jun 24th, 2022 16:00 DELAYED
BID291.49 ASK295.00
Open286.26 Previous Close283.50
Pre-Market- After-Market280.00
 - -  -12.55 -4.29%
Target Price
289.22 
Analyst Rating
Moderate Buy 1.78
Potential %
-1.14 
Finscreener Ranking
★★★     49.09
Insiders Trans % 3/6/12 mo.
-100/-100/-96 
Value Ranking
★★★★     55.47
Insiders Value % 3/6/12 mo.
-100/-100/-67 
Growth Ranking
★★★★★     70.25
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-59 
Income Ranking
 —    -
Price Range Ratio 52W %
99.83 
Earnings Rating
Sell
Market Cap74.82B 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.08
Beta0.55 

Today's Price Range

280.28293.17

52W Range

176.36292.75

5 Year PE Ratio Range

-159.40185.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
11.20%
1 Month
8.02%
3 Months
15.20%
6 Months
30.92%
1 Year
47.70%
3 Years
62.39%
5 Years
119.14%
10 Years
400.68%

TickerPriceChg.Chg.%
VRTX292.559.05003.19
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
4.40
4.80
0.07
0.08
48.20
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
88.00
36.80
38.50
29.80
30.84
RevenueValueIndustryS&P 500US Markets
7.95B
31.07
30.50
30.78
Earnings HistoryEstimateReportedSurprise %
Q01 20223.173.16-0.32
Q04 20212.913.189.28
Q03 20212.743.2518.61
Q02 20212.252.8024.44
Q01 20212.382.546.72
Q04 20202.332.22-4.72
Q03 20202.022.3616.83
Q02 20201.752.2629.14
Earnings Per EndEstimateRevision %Trend
6/2022 QR3.16-0.94Negative
9/2022 QR3.19-0.31Negative
12/2022 FY12.47-1.27Negative
12/2023 FY13.333.90Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report3.16
Estimates Count9
EPS Growth Next 5 Years %10.90
Volume Overview
Volume3.02M
Shares Outstanding255.76K
Shares Float255.44M
Trades Count47.49K
Dollar Volume872.95M
Avg. Volume1.75M
Avg. Weekly Volume2.09M
Avg. Monthly Volume1.52M
Avg. Quarterly Volume1.63M

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stock closed at 292.55 per share at the end of the most recent trading day (a 3.19% change compared to the prior day closing price) with a volume of 3.02M shares and market capitalization of 74.82B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3400 people. Vertex Pharmaceuticals Incorporated CEO is Reshma Kewalramani.

The one-year performance of Vertex Pharmaceuticals Incorporated stock is 47.7%, while year-to-date (YTD) performance is 33.22%. VRTX stock has a five-year performance of 119.14%. Its 52-week range is between 176.36 and 292.75, which gives VRTX stock a 52-week price range ratio of 99.83%

Vertex Pharmaceuticals Incorporated currently has a PE ratio of 27.80, a price-to-book (PB) ratio of 6.17, a price-to-sale (PS) ratio of 8.47, a price to cashflow ratio of 25.40, a PEG ratio of 2.32, a ROA of 18.59%, a ROC of 23.07% and a ROE of 24.65%. The company’s profit margin is 30.84%, its EBITDA margin is 38.50%, and its revenue ttm is $7.95 Billion , which makes it $31.07 revenue per share.

Of the last four earnings reports from Vertex Pharmaceuticals Incorporated, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $3.16 for the next earnings report. Vertex Pharmaceuticals Incorporated’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Vertex Pharmaceuticals Incorporated is Moderate Buy (1.78), with a target price of $289.22, which is -1.14% compared to the current price. The earnings rating for Vertex Pharmaceuticals Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Vertex Pharmaceuticals Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Vertex Pharmaceuticals Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 6.00, ATR14 : 9.31, CCI20 : 173.87, Chaikin Money Flow : 0.22, MACD : 3.77, Money Flow Index : 72.50, ROC : 7.61, RSI : 67.60, STOCH (14,3) : 98.76, STOCH RSI : 1.00, UO : 71.95, Williams %R : -1.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Vertex Pharmaceuticals Incorporated in the last 12-months were: Amit K. Sachdev (Sold 51 shares of value $9 547 ), Bastiano Sanna (Sold 7 834 shares of value $2 067 991 ), Bruce I. Sachs (Buy at a value of $2 968 650), Charles F. Wagner (Sold 9 040 shares of value $2 301 804 ), David Altshuler (Option Excercise at a value of $403 183), David Altshuler (Sold 21 319 shares of value $5 030 040 ), Jeffrey M Leiden (Sold 15 789 shares of value $4 563 652 ), Joy Liu (Sold 253 shares of value $66 682 ), Kristen Ambrose (Sold 327 shares of value $88 143 ), Margaret G. McGlynn (Option Excercise at a value of $1 275 400), Margaret G. McGlynn (Sold 15 000 shares of value $3 921 386 ), Ourania Tatsis (Sold 3 967 shares of value $971 694 ), Reshma Kewalramani (Buy at a value of $1 956 492), Sangeeta N. Bhatia (Option Excercise at a value of $239 729), Sangeeta N. Bhatia (Sold 2 524 shares of value $694 014 ), Stuart A. Arbuckle (Sold 422 shares of value $109 754 ), Yuchun Lee (Option Excercise at a value of $1 630 800), Yuchun Lee (Sold 19 100 shares of value $5 315 682 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (61.11 %)
11 (61.11 %)
12 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
7 (38.89 %)
7 (38.89 %)
5 (27.78 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (5.56 %)
Summary RatingModerate Buy
1.78
Moderate Buy
1.78
Moderate Buy
1.74

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex's pipeline includes gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. Vertex also has an expanding research pipeline focused on inflammatory diseases, non-opioid treatments for pain, and genetic and cell therapies for type 1 diabetes and rare diseases.

CEO: Reshma Kewalramani

Telephone: +1 617 341-6100

Address: 50 Northern Avenue, Boston 02210, MA, US

Number of employees: 3 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

63%37%

Bearish Bullish

58%42%

TipRanks News for VRTX

Tue, 14 Jun 2022 01:45 GMT Vertex Pharmaceuticals (VRTX) Gets a Hold Rating from RBC Capital

- TipRanks. All rights reserved.

Mon, 13 Jun 2022 10:25 GMT Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Wed, 08 Jun 2022 16:35 GMT Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Aldeyra Therapeutics (ALDX)

- TipRanks. All rights reserved.

Mon, 09 May 2022 15:17 GMT Vertex Pharmaceuticals (VRTX) Gets a Buy Rating from Evercore ISI

- TipRanks. All rights reserved.

Fri, 01 Apr 2022 10:17 GMT H.C. Wainwright Believes Vertex Pharmaceuticals (VRTX) Still Has Room to Grow

- TipRanks. All rights reserved.

Thu, 24 Mar 2022 14:56 GMT Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Vertex Pharmaceuticals (VRTX) and Relmada Therapeutics (RLMD)

- TipRanks. All rights reserved.

Wed, 23 Mar 2022 11:45 GMT Analysts Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Argenx Se (ARGX)

- TipRanks. All rights reserved.

Sun, 27 Feb 2022 15:20 GMT Vertex Pharmaceuticals: Shares Up as Business Expands

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 01:49 GMT Vertex Pharmaceuticals (VRTX) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits